Aurora Cannabis (TSE:ACB) Downgraded by TD Securities to Strong Sell

TD Securities lowered shares of Aurora Cannabis (TSE:ACB) from a strong-buy rating to a strong sell rating in a research note released on Tuesday,Zacks reports.

Other equities research analysts have also issued research reports about the stock. TD lowered shares of Aurora Cannabis from a “buy” rating to a “sell” rating and cut their price target for the stock from C$8.00 to C$7.80 in a report on Wednesday. ATB Cormark Capital Markets upped their price objective on shares of Aurora Cannabis from C$5.60 to C$7.00 and gave the company a “tender” rating in a research note on Tuesday, October 6th. Finally, BMO Capital Markets raised shares of Aurora Cannabis to a “hold” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and an average price target of C$6.60.

Aurora Cannabis Stock Performance

Shares of ACB stock opened at C$7.31 on Tuesday. The company has a debt-to-equity ratio of 4.30, a quick ratio of 2.48 and a current ratio of 5.36. Aurora Cannabis has a fifty-two week low of C$3.59 and a fifty-two week high of C$8.75. The stock has a 50 day moving average price of C$5.76 and a two-hundred day moving average price of C$4.95. The company has a market capitalization of C$452.91 million, a P/E ratio of -3.77 and a beta of 0.64.

Aurora Cannabis (TSE:ACB) last issued its earnings results on Wednesday, August 5th. The company reported C($0.07) earnings per share (EPS) for the quarter. The firm had revenue of C$67.55 million during the quarter. Aurora Cannabis had a negative return on equity of 5.21% and a negative net margin of 9.53%. Analysts expect that Aurora Cannabis will post -0.22 earnings per share for the current year.

More Aurora Cannabis News

Here are the key news stories impacting Aurora Cannabis this week:

• Positive Sentiment: Organigram agreed to acquire Aurora in a cash-and-stock transaction valued at about C$561 million, offering C$7.80 per share—a reported 93% premium to Aurora’s unaffected share price. The bid topped Curaleaf’s competing hostile offer by 21%, supporting investor interest in the shares. Article: Organigram outbids Curaleaf with C$561M deal for Aurora Cannabis
• Neutral Sentiment: The C$7.80 offer provides a clear transaction value, but the deal remains subject to completion of the arrangement process; the provided reports do not detail the remaining conditions. Article: Organigram to Acquire Aurora and Establish a Global Cannabis Leader
• Negative Sentiment: TD cut Aurora to “sell” from “buy” and lowered its price target to C$7.80 from C$8.00. The downgrade may weigh on sentiment, even though the new target was cited as implying upside from the share price at the time of the rating. Article: TD stock recommendations

About Aurora Cannabis

Aurora is Opening the World to Cannabis ¿, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company’s adult-use brand portfolio includes Drift , San Raf , Daily Special ¿, Tasty’s ¿, Being and Greybeard . Medical cannabis brands include MedReleaf , CanniMed , Aurora and Whistler Medical Marijuana Corporation , as well as international brands, Pedanios , IndiMed ¿ and CraftPlant ¿.